These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 34217426)

  • 21. Sexual behaviour and incidence of HIV and sexually transmitted infections among men who have sex with men using daily and event-driven pre-exposure prophylaxis in AMPrEP: 2 year results from a demonstration study.
    Hoornenborg E; Coyer L; Achterbergh RCA; Matser A; Schim van der Loeff MF; Boyd A; van Duijnhoven YTHP; Bruisten S; Oostvogel P; Davidovich U; Hogewoning A; Prins M; de Vries HJC;
    Lancet HIV; 2019 Jul; 6(7):e447-e455. PubMed ID: 31178284
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HIV pre-exposure prophylaxis and its implementation in the PrEP Impact Trial in England: a pragmatic health technology assessment.
    Sullivan AK; Saunders J; Desai M; Cartier A; Mitchell HD; Jaffer S; Ogaz D; Chiavenna C; Charlett A; Diamente V; Golombek R; Manavi K; Priestley C; Waters LJ; Milinkovic A; McOwan A; Estcourt C; Sabin CA; Rodger A; Gold D; Gazzard BG; McCormack S; Gill ON;
    Lancet HIV; 2023 Dec; 10(12):e790-e806. PubMed ID: 38040478
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Community-level changes in condom use and uptake of HIV pre-exposure prophylaxis by gay and bisexual men in Melbourne and Sydney, Australia: results of repeated behavioural surveillance in 2013-17.
    Holt M; Lea T; Mao L; Kolstee J; Zablotska I; Duck T; Allan B; West M; Lee E; Hull P; Grulich A; De Wit J; Prestage G
    Lancet HIV; 2018 Aug; 5(8):e448-e456. PubMed ID: 29885813
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acceptability, safety, and patterns of use of oral tenofovir disoproxil fumarate and emtricitabine for HIV pre-exposure prophylaxis in South African adolescents: an open-label single-arm phase 2 trial.
    Gill K; Johnson L; Dietrich J; Myer L; Marcus R; Wallace M; Pidwell T; Mendel E; Fynn L; Jones K; Wiesner L; Slack C; Strode A; Spiegel H; Hosek S; Rooney J; Gray G; Bekker LG
    Lancet Child Adolesc Health; 2020 Dec; 4(12):875-883. PubMed ID: 33222803
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High Levels of Prevention-Effective Adherence to HIV PrEP: An Analysis of Substudy Data From the EPIC-NSW Trial.
    Bavinton BR; Vaccher S; Jin F; Prestage GP; Holt M; Zablotska-Manos IB; Guy R; Amin J; Templeton DJ; Yeung B; Hammoud MA; Lewis D; Baker D; Dharan N; McNulty AM; Grulich AE;
    J Acquir Immune Defic Syndr; 2021 Aug; 87(4):1040-1047. PubMed ID: 33852503
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of HIV pre-exposure prophylaxis among men who have sex with men in England: data from the AURAH2 prospective study.
    Hanum N; Cambiano V; Sewell J; Phillips AN; Rodger AJ; Speakman A; Nwokolo N; Asboe D; Gilson R; Clarke A; Miltz AR; Collins S; Lampe FC;
    Lancet Public Health; 2020 Sep; 5(9):e501-e511. PubMed ID: 32888443
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Trends in HIV incidence between 2013-2019 and association of baseline factors with subsequent incident HIV among gay, bisexual, and other men who have sex with men attending sexual health clinics in England: A prospective cohort study.
    Hanum N; Cambiano V; Sewell J; Rodger AJ; Nwokolo N; Asboe D; Gilson R; Clarke A; Miltz AR; Collins S; Delpech V; Croxford S; Phillips AN; Lampe FC;
    PLoS Med; 2021 Jun; 18(6):e1003677. PubMed ID: 34143781
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NZPrEP Demonstration Project: protocol for an open-label, single-arm trial of HIV pre-exposure prophylaxis (PrEP) to determine feasibility, acceptability, adverse and behavioural effects of PrEP provision to gay and bisexual men in publicly funded sexual health clinics in Auckland, New Zealand.
    Azariah S; Saxton P; Franklin R; Forster R; Werder S; Jenkins R
    BMJ Open; 2019 Jun; 9(6):e026363. PubMed ID: 31248921
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictors of Daily Adherence to HIV Pre-exposure Prophylaxis in Gay/Bisexual Men in the PRELUDE Demonstration Project.
    Vaccher SJ; Marzinke MA; Templeton DJ; Haire BG; Ryder N; McNulty A; Foster R; Grulich AE; Zablotska IB; ;
    AIDS Behav; 2019 May; 23(5):1287-1296. PubMed ID: 30523489
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bacterial sexually transmitted infections among men who have sex with men and transgender women using oral pre-exposure prophylaxis in Latin America (ImPrEP): a secondary analysis of a prospective, open-label, multicentre study.
    Torres Silva MS; Torres TS; Coutinho C; Ismério Moreira R; da Costa Leite I; Cunha M; da Costa Leite PHA; Cáceres CF; Vega-Ramírez H; Konda KA; Guanira J; Valdez Madruga J; Wagner Cardoso S; Benedetti M; Pimenta MC; Hoagland B; Grinsztejn B; Gonçalves Veloso V;
    Lancet HIV; 2024 Oct; 11(10):e670-e679. PubMed ID: 39243787
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HIV incidence after pre-exposure prophylaxis initiation among women and men at elevated HIV risk: A population-based study in rural Kenya and Uganda.
    Koss CA; Havlir DV; Ayieko J; Kwarisiima D; Kabami J; Chamie G; Atukunda M; Mwinike Y; Mwangwa F; Owaraganise A; Peng J; Olilo W; Snyman K; Awuonda B; Clark TD; Black D; Nugent J; Brown LB; Marquez C; Okochi H; Zhang K; Camlin CS; Jain V; Gandhi M; Cohen CR; Bukusi EA; Charlebois ED; Petersen ML; Kamya MR; Balzer LB
    PLoS Med; 2021 Feb; 18(2):e1003492. PubMed ID: 33561143
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Trends in Attitudes to and the Use of HIV Pre-exposure Prophylaxis by Australian Gay and Bisexual Men, 2011-2017: Implications for Further Implementation from a Diffusion of Innovations Perspective.
    Holt M; Lea T; Bear B; Halliday D; Ellard J; Murphy D; Kolstee J; de Wit J
    AIDS Behav; 2019 Jul; 23(7):1939-1950. PubMed ID: 30539496
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Validation of participant eligibility for pre-exposure prophylaxis: Baseline data from the PRELUDE demonstration project.
    Vaccher SJ; Grulich AE; Haire BG; Conway DP; Poynten IM; Ooi C; Foster R; Templeton DJ; Zablotska IB;
    PLoS One; 2017; 12(9):e0185398. PubMed ID: 28950022
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Willingness to Take PrEP and Potential for Risk Compensation Among Highly Sexually Active Gay and Bisexual Men.
    Grov C; Whitfield TH; Rendina HJ; Ventuneac A; Parsons JT
    AIDS Behav; 2015 Dec; 19(12):2234-44. PubMed ID: 25735243
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Study on Pre-Exposure Prophylaxis Regimens among Men Who Have Sex with Men: A Prospective Cohort Study.
    Wu D; Tao H; Dai J; Liang H; Huang A; Zhong X
    Int J Environ Res Public Health; 2019 Dec; 16(24):. PubMed ID: 31818006
    [No Abstract]   [Full Text] [Related]  

  • 36. Anti-retroviral Therapy Based HIV Prevention Among a Sample of Men Who Have Sex with Men in Cape Town, South Africa: Use of Post-exposure Prophylaxis and Knowledge on Pre-exposure Prophylaxis.
    Hugo JM; Stall RD; Rebe K; Egan JE; De Swardt G; Struthers H; McIntyre JA
    AIDS Behav; 2016 Dec; 20(Suppl 3):357-364. PubMed ID: 27631366
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early experience of implementing a national HIV pre-exposure prophylaxis service in Wales, United Kingdom 2017.
    Fina L; Phillips AL; Jones AT; Couzens ZM; Drayton R; Thomas DR; Shankar AG
    Sex Health; 2019 Feb; 16(1):56-62. PubMed ID: 30501846
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Incorporating oral PrEP into standard prevention services for South African women: a nested interrupted time-series study.
    Donnell D; Beesham I; Welch JD; Heffron R; Pleaner M; Kidoguchi L; Palanee-Phillips T; Ahmed K; Baron D; Bukusi EA; Louw C; Mastro TD; Smit J; Batting JR; Malahleha M; Bailey VC; Beksinska M; Rees H; Baeten JM;
    Lancet HIV; 2021 Aug; 8(8):e495-e501. PubMed ID: 34126052
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Factors associated with the uptake of and adherence to HIV pre-exposure prophylaxis in people who have injected drugs: an observational, open-label extension of the Bangkok Tenofovir Study.
    Martin M; Vanichseni S; Suntharasamai P; Sangkum U; Mock PA; Chaipung B; Worrajittanon D; Leethochawalit M; Chiamwongpaet S; Kittimunkong S; Gvetadze RJ; McNicholl JM; Paxton LA; Curlin ME; Holtz TH; Samandari T; Choopanya K;
    Lancet HIV; 2017 Feb; 4(2):e59-e66. PubMed ID: 27866873
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Uptake, engagement, and adherence to pre-exposure prophylaxis offered after population HIV testing in rural Kenya and Uganda: 72-week interim analysis of observational data from the SEARCH study.
    Koss CA; Charlebois ED; Ayieko J; Kwarisiima D; Kabami J; Balzer LB; Atukunda M; Mwangwa F; Peng J; Mwinike Y; Owaraganise A; Chamie G; Jain V; Sang N; Olilo W; Brown LB; Marquez C; Zhang K; Ruel TD; Camlin CS; Rooney JF; Black D; Clark TD; Gandhi M; Cohen CR; Bukusi EA; Petersen ML; Kamya MR; Havlir DV;
    Lancet HIV; 2020 Apr; 7(4):e249-e261. PubMed ID: 32087152
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.